MCRB – Seres Therapeutics, Inc.

Seres Therapeutics, Inc.

MCRB

$0.7674

Name : Seres Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $131,024,344.00

EPSttm : -0.4

Seres Therapeutics, Inc.

$0.7674

4.41%

$0.0324

Float Short %

16.38

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

0.14

EPS Last/This Y

0.37

EPS This/Next Y

0.11

Price

0.77

Target Price

3.31

Analyst Recom

2.25

Performance Q

-8.92

Relative Volume

0.31

Beta

2.11

Ticker: MCRB

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	MCRB	0.9333	0.09	0.00	65729
2024-12-20	MCRB	0.923	0.09	0.02	66432
2024-12-23	MCRB	0.9654	0.08	0.00	62013
2024-12-24	MCRB	0.96	0.08	0.00	62449
2024-12-26	MCRB	0.9287	0.08	0.00	62541
2024-12-27	MCRB	0.8871	0.08	0.09	62622
2024-12-30	MCRB	0.8384	0.08	0.05	62937
2024-12-31	MCRB	0.8389	0.08	0.70	62982
2025-01-02	MCRB	0.8368	0.08	0.02	62948
2025-01-03	MCRB	0.899	0.08	0.33	63370
2025-01-06	MCRB	0.9115	0.08	0.00	63680
2025-01-07	MCRB	0.8674	0.08	0.03	63918
2025-01-08	MCRB	0.855	0.08	0.00	63921
2025-01-09	MCRB	0.85	0.08	0.00	63921
2025-01-10	MCRB	0.8453	0.07	0.01	64647
2025-01-13	MCRB	0.8289	0.07	0.01	64637
2025-01-14	MCRB	0.7663	0.07	2.57	65066
2025-01-15	MCRB	0.7873	0.07	0.08	65059
2025-01-16	MCRB	0.7489	0.07	0.02	65179
2025-01-17	MCRB	0.7701	0.06	0.01	65231
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	MCRB	0.92	22.5	-	-0.52
2024-12-20	MCRB	0.93	22.5	-	-0.52
2024-12-23	MCRB	0.97	22.5	-	-0.52
2024-12-24	MCRB	0.96	22.5	-	-0.52
2024-12-26	MCRB	0.92	22.5	-	-0.52
2024-12-27	MCRB	0.89	22.5	-	-0.52
2024-12-30	MCRB	0.84	22.5	-	-0.52
2024-12-31	MCRB	0.83	22.5	-	-0.52
2025-01-02	MCRB	0.84	22.5	-	-0.52
2025-01-03	MCRB	0.90	22.5	-	-0.52
2025-01-06	MCRB	0.91	22.5	-	-0.52
2025-01-07	MCRB	0.87	22.5	-	-0.52
2025-01-08	MCRB	0.85	22.5	-	-0.52
2025-01-09	MCRB	0.85	22.5	-	-0.52
2025-01-10	MCRB	0.84	22.5	-	-0.52
2025-01-13	MCRB	0.82	22.5	-	-0.52
2025-01-14	MCRB	0.77	22.5	-	-0.52
2025-01-15	MCRB	0.78	22.5	-	-0.52
2025-01-16	MCRB	0.74	22.5	-	-0.52
2025-01-17	MCRB	0.77	22.5	-	-0.52
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	MCRB	-0.13	-12.91	13.93
2024-12-20	MCRB	-0.13	-12.91	13.93
2024-12-23	MCRB	-0.14	-12.91	13.93
2024-12-24	MCRB	-0.14	-12.91	13.93
2024-12-26	MCRB	-0.14	-12.91	15.71
2024-12-27	MCRB	-0.13	-12.91	15.71
2024-12-30	MCRB	-0.14	-12.33	15.71
2024-12-31	MCRB	-0.14	-12.33	15.71
2025-01-02	MCRB	-0.13	-12.33	15.71
2025-01-03	MCRB	-0.13	-12.33	15.71
2025-01-06	MCRB	-0.13	-13.10	15.71
2025-01-07	MCRB	-0.13	-13.10	15.71
2025-01-08	MCRB	-0.13	-13.10	15.71
2025-01-09	MCRB	-0.13	-13.10	15.71
2025-01-10	MCRB	-0.13	-13.10	15.71
2025-01-13	MCRB	-0.13	-13.10	16.38
2025-01-14	MCRB	-0.13	-13.10	16.38
2025-01-15	MCRB	-0.13	-13.10	16.38
2025-01-16	MCRB	-0.13	-13.10	16.38
2025-01-17	MCRB	-0.13	-13.10	16.38
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.33

Avg. EPS Est. Current Quarter

-0.21

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

-0.13

Institutional Transactions

-13.1

Beta

2.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-98.5

Target Price

3.31

P/E

Forward P/E

PEG

P/S

2183.7

P/B

5.46

P/Free Cash Flow

EPS

-1.19

Average EPS Est. Cur. Y

-0.52

EPS Next Y. (Est.)

-0.41

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-269034.37

Relative Volume

0.31

Return on Equity vs Sector %

-125.6

Return on Equity vs Industry %

-113

EPS 1 7Days Diff

EPS 1 30Days Diff

0.16

EBIT Estimation

Seres Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 233

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today

news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance

stock history MCRB – Seres Therapeutics, Inc. invest stock market

stock prices MCRB premarket after hours

ticker MCRB fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

MCRB – Seres Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MCRB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y